Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation

Food Funct. 2019 Jul 17;10(7):4062-4070. doi: 10.1039/c9fo00695h.


Herein, the potential of hydrolysates of chicken feet proteins as natural dipeptidyl-peptidase IV (DPP-IV) inhibitors was investigated; moreover, three hydrolysates were selected due to their high DPP-IV inhibitory capacity (>80% inhibition), showing the IC50 values of around 300 μg estimated protein per mL; one of them (named p4H) was selected for the posterior analysis. In addition, its effect on glucose tolerance was investigated in two rat models (diet and age-induced) of glucose-intolerance and healthy animals; the amount of 300 mg estimated peptide per kg body weight improved the plasma glucose profile in both glucose-intolerance models. Moreover, it stimulated active GLP-1 release in the enteroendocrine STC-1 cells and rat ileum tissue. In conclusion, our results indicate that chicken feet proteins are a good source of bioactive peptides as DPP-IV inhibitors. Moreover, our results highlight the potential of the selected hydrolysate p4H in the management of type 2 diabetes due to its dual function of inhibition of the DPP-IV activity and induction of the GLP-1 release.

MeSH terms

  • Animals
  • Blood Glucose
  • Body Weight
  • Cell Line
  • Chickens / metabolism*
  • Diabetes Mellitus, Type 2
  • Diet
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
  • Disease Models, Animal
  • Drug Delivery Systems
  • Female
  • Foot*
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose Intolerance
  • Hypoglycemic Agents / pharmacology*
  • Incretins / pharmacology*
  • Inhibitory Concentration 50
  • Male
  • Protein Hydrolysates / metabolism*
  • Rats
  • Rats, Wistar


  • Blood Glucose
  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Incretins
  • Protein Hydrolysates
  • Glucagon-Like Peptide 1